ClinicalTrials.gg
CompletedNCT00753545Updated Feb 3, 2025Results posted

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

A Phase 2 interventional study of AZD2281 and matching placebo in Ovarian Cancer, sponsored by AstraZeneca. Completed at 107 sites in 17 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
15th of 69
265 · median 96
Started
2008
with 3 others
Phase 2
32 of 69
7 open now
Registered
6th of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 15th largest by enrollment, is one of 4 that started in 2008, is one of 32 in phase 2, and was the 6th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy

03

Conditions studied

  • Ovarian Cancer

Keywords

  • Serous,
  • Ovarian cancer,
  • PARP,
  • BRCA1,
  • BRCA2,
  • Poly(ADP ribose) polymerases,
  • Platinum sensitive,
  • Homologous Recombination Deficiency (HRD)
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients with diagnosed serous ovarian cancer or recurrent serous ovarian cancer.
  • Patients must have completed at least 2 previous courses of platinum containing therapy; the patient must have been platinum sensitive to the penultimate chemo regimen.
  • For the last chemotherapy course prior to enrolment on the study, patients must have demonstrated an objective stable maintained response (partial or complete response) and this response needs to be maintained until completion of chemotherapy.
  • Patients must be treated on the study within 8 wks of completion of their final dose of the platinum containing regimen.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with PARP inhibitors including AZD2281
  • Patients with low grade ovarian carcinoma.
  • Patients who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen prior to enrolment on the study
  • Patients receiving any chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study entry (or a longer period depending on the defined characteristics of the agents used).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    1

    AZD2281

    Drug: AZD2281

  • Placebo comparator
    2

    matching placebo

    Drug: matching placebo

Interventions

  • Tablets Oral BID

    Also known as: Olaparib, Lynparza

  • Drugmatching placebo

    matching placebo bid

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST])

    PFS was defined as the time from randomisation to the earlier date of radiological progression (per RECIST criteria) or death by any cause in the absence of objective progression. \[Full analysis set (FAS)\]

    Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.

Secondary outcomes

  1. Overall Survival (OS)

    OS = time from randomisation to date of death from any cause. Patients who had not died at time of analysis were censored at last date patient was known to be alive.

    Time frame: Follow up every 12 weeks post progression, assessed maximum up to 90 months.

  2. Objective Response Rate (ORR) (According to RECIST)

    For each treatment group, the ORR was the number of Complete Response (CR) and Partial Response (PR) divided by the number of patients in the group in the FAS with measurable disease at baseline (displayed as a percentage below). Evaluable for response set

    Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.

  3. Disease Control Rate

    Disease control rate was defined as the percentage of patients who have at least 1 confirmed visit response of CR or PR or have demonstrated SD or NED for at least 23 weeks (ie, 24 weeks +/- 1 week) prior to any evidence of progression. \[FAS\]

    Time frame: Assessed at 24 weeks. Radiologic scans performed at baseline, week 12 (+/- 1 week) and week 24 (+/- 1 week).

  4. Duration of Response

    Duration of response = time from assessment prior to timepoint where PR or CR confirmed (i.e. initial assessment of PR/CR), until earliest date of objective progression or death. \[Responding patients only\]. There were insufficient responses to enable conclusions to be drawn.

    Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.

  5. Percentage Change From Baseline in Tumour Size at Week 24

    Percentage change from baseline to Week 24 in target tumour size.

    Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.

  6. Best Percentage Change in Cancer Antigen 125 (CA-125) Levels

    Best percentage change from baseline in CA-125 level

    Time frame: CA-125 was measured at baseline then every 28 days on treatment, assessed maximum up to 14 months.

  7. Best Objective Response

    Best overall response from radiologic assessments. \[FAS\]

    Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1week) for the first 60 weeks, then every 24 weeks (+/- 1 week) thereafter, assessed maximum up to 14 months.

  8. RECIST and CA-125 Response Separately and Combined

    RECIST and CA-125 response separately and combined \[Patients evaluable for either CA-125 response or RECIST response\]

    Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1week) for the first 60 weeks, then every 24 weeks (+/- 1 week) thereafter and monthly for CA-125 measurements, assessed maximum up to 14 months.

  9. Time to Earlier of CA-125 or RECIST Progression

    Time from randomisation to the earlier date of radiological progression (per RECIST criteria) or CA-125 or death by any cause in the absence of objective progression. \[FAS\]

    Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/- 1 week) thereafter and monthly for CA-125 measurements, assessed maximum up to 14 months.

  10. Improvement Rate for FACT-O Symptom Index (FOSI)

    The percentage of patients with an improvement in FOSI. Improvement was defined as a change from baseline of greater than or equal to +3. \[Evaluable for FOSI set\]

    Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.

  11. Improvement Rate for Trial Outcome Index (TOI)

    The percentage of patients with an improvement in TOI. Improvement was defined as a change from baseline of greater than or equal to +7. \[Evaluable for TOI set\]

    Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.

  12. Improvement Rate for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)

    The percentage of patients with an improvement in total FACT-O. Improvement was defined as a change from baseline of greater than or equal to +9. \[Evaluable for FACT-O set\]

    Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.

  13. FACT-O Symptom Index (FOSI) Time to Worsening

    The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for FOSI set\]

    Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.

  14. Trial Outcome Index(TOI)Time to Worsening

    The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for TOI set\]

    Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.

  15. Functional Analysis of Cancer Therapy - Ovarian (FACT-O) Time to Worsening

    The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for FACT-O set\]

    Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.

07

Results

Posted Mar 11, 2013
Limitations and caveats
For OM DoR: The subset of patients evaluable for response who responded to study treatment.Values in results table may be under-estimates as some patients had not progressed at final analysis,so true duration is likely to be greater than in database.

Participant flow

The first patient was enrolled on 28 August 2008 and the last patient was enrolled on 9 February 2010. Patients were enrolled at 82 centres in 16 countries. Of the 326 patients enrolled, 265 were randomized

Participant flow — Overall Study
MilestoneOlaparib 400 mg bdPlacebo bd
Started136129
Completed2811
Not completed108118
Withdrew: Death98112
Withdrew: Lost to follow-up23
Withdrew: Protocol violation10
Withdrew: Voluntary discontinuation of patient73

Outcome measures

PrimaryProgression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST])

PFS was defined as the time from randomisation to the earlier date of radiological progression (per RECIST criteria) or death by any cause in the absence of objective progression. \[Full analysis set (FAS)\]

Time frame:
Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.
Reported as:
Median · Months
Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST])
MonthsOlaparib 400 mg bdPlacebo bd
Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST])8.4 (7.4 to 11.5)4.8 (4.0 to 5.5)
Statistical analysis
  • Olaparib 400 mg bd vs Placebo bd · Regression, Cox · p = <0.00001 · Hazard ratio (hr): 0.35 · 95% CI 0.25 to 0.49The model includes factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy.
SecondaryOverall Survival (OS)

OS = time from randomisation to date of death from any cause. Patients who had not died at time of analysis were censored at last date patient was known to be alive.

Time frame:
Follow up every 12 weeks post progression, assessed maximum up to 90 months.
Reported as:
Median · Months
Overall Survival (OS)
MonthsOlaparib 400 mg bdPlacebo bd
Overall Survival (OS)29.8 (26.9 to 35.7)27.8 (24.9 to 33.7)
Statistical analysis
  • Olaparib 400 mg bd vs Placebo bd · Regression, Cox · p = 0.02 · Hazard ratio (hr): 0.73 · 95% CI 0.55 to 0.95The model includes factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy.
SecondaryObjective Response Rate (ORR) (According to RECIST)

For each treatment group, the ORR was the number of Complete Response (CR) and Partial Response (PR) divided by the number of patients in the group in the FAS with measurable disease at baseline (displayed as a percentage below). Evaluable for response set

Time frame:
Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) (According to RECIST)
percentage of participantsOlaparib 400 mg bdPlacebo bd
Objective Response Rate (ORR) (According to RECIST)12.34.2
SecondaryDisease Control Rate

Disease control rate was defined as the percentage of patients who have at least 1 confirmed visit response of CR or PR or have demonstrated SD or NED for at least 23 weeks (ie, 24 weeks +/- 1 week) prior to any evidence of progression. \[FAS\]

Time frame:
Assessed at 24 weeks. Radiologic scans performed at baseline, week 12 (+/- 1 week) and week 24 (+/- 1 week).
Reported as:
Number · percentage of participants
Disease Control Rate
percentage of participantsOlaparib 400 mg bdPlacebo bd
Disease Control Rate53.725.6
SecondaryDuration of Response

Duration of response = time from assessment prior to timepoint where PR or CR confirmed (i.e. initial assessment of PR/CR), until earliest date of objective progression or death. \[Responding patients only\]. There were insufficient responses to enable conclusions to be drawn.

Time frame:
Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.
Reported as:
Median · Months
Duration of Response
MonthsOlaparib 400 mg bdPlacebo bd
Duration of Response4.2 (2.8 to 5.6)2.3 (1.8 to 2.8)
SecondaryPercentage Change From Baseline in Tumour Size at Week 24

Percentage change from baseline to Week 24 in target tumour size.

Time frame:
Radiologic scans performed at baseline then every 12 weeks (+/- 1week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.
Reported as:
Least squares mean · Percent change in tumour size
Percentage Change From Baseline in Tumour Size at Week 24
Percent change in tumour sizeOlaparib 400 mg bdPlacebo bd
Percentage Change From Baseline in Tumour Size at Week 24-0.8 (-100.0 to 45.0)26.4 (-36.4 to 39.4)
Statistical analysis
  • Olaparib 400 mg bd vs Placebo bd · ANCOVA · p = 0.03185 · Difference in ls means: -27.1 · 95% CI -51.9 to -2.4The model includes factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy.
SecondaryBest Percentage Change in Cancer Antigen 125 (CA-125) Levels

Best percentage change from baseline in CA-125 level

Time frame:
CA-125 was measured at baseline then every 28 days on treatment, assessed maximum up to 14 months.
Reported as:
Median · percentage of change
Best Percentage Change in Cancer Antigen 125 (CA-125) Levels
percentage of changeOlaparib 400 mg bdPlacebo bd
Best Percentage Change in Cancer Antigen 125 (CA-125) Levels-16.67 (-100.00 to 346.15)0.00 (-99.50 to 1436.84)
SecondaryBest Objective Response

Best overall response from radiologic assessments. \[FAS\]

Time frame:
Radiologic scans performed at baseline then every 12 weeks (+/- 1week) for the first 60 weeks, then every 24 weeks (+/- 1 week) thereafter, assessed maximum up to 14 months.
Reported as:
Number · Participants
Best Objective Response
ParticipantsOlaparib 400 mg bdPlacebo bd
Complete Response00
Partial Response72
No evidence of disease4942
Stable Disease >= 11 weeks4625
Disease Progression2455
Not Evaluable105
SecondaryRECIST and CA-125 Response Separately and Combined

RECIST and CA-125 response separately and combined \[Patients evaluable for either CA-125 response or RECIST response\]

Time frame:
Radiologic scans performed at baseline then every 12 weeks (+/- 1week) for the first 60 weeks, then every 24 weeks (+/- 1 week) thereafter and monthly for CA-125 measurements, assessed maximum up to 14 months.
Reported as:
Number · Participants
RECIST and CA-125 Response Separately and Combined
ParticipantsOlaparib 400 mg bdPlacebo bd
RECIST Response162
Confirmed RECIST Response72
Unconfirmed RECIST response90
CA-125 Response11
Confirmed RECIST or CA-125 Response83
SecondaryTime to Earlier of CA-125 or RECIST Progression

Time from randomisation to the earlier date of radiological progression (per RECIST criteria) or CA-125 or death by any cause in the absence of objective progression. \[FAS\]

Time frame:
Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/- 1 week) thereafter and monthly for CA-125 measurements, assessed maximum up to 14 months.
Reported as:
Median · Months
Time to Earlier of CA-125 or RECIST Progression
MonthsOlaparib 400 mg bdPlacebo bd
Time to Earlier of CA-125 or RECIST Progression8.3 (5.5 to 10.3)3.7 (2.8 to 4.5)
Statistical analysis
  • Olaparib 400 mg bd vs Placebo bd · Regression, Cox · p = <0.00001 · Hazard ratio (hr): 0.35 · 95% CI 0.25 to 0.47The model includes factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy.
SecondaryImprovement Rate for FACT-O Symptom Index (FOSI)

The percentage of patients with an improvement in FOSI. Improvement was defined as a change from baseline of greater than or equal to +3. \[Evaluable for FOSI set\]

Time frame:
Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
Reported as:
Number · percentage of evaluable participants
Improvement Rate for FACT-O Symptom Index (FOSI)
percentage of evaluable participantsOlaparib 400 mg bdPlacebo bd
Improvement Rate for FACT-O Symptom Index (FOSI)17.114.8
SecondaryImprovement Rate for Trial Outcome Index (TOI)

The percentage of patients with an improvement in TOI. Improvement was defined as a change from baseline of greater than or equal to +7. \[Evaluable for TOI set\]

Time frame:
Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
Reported as:
Number · percentage of evaluable participants
Improvement Rate for Trial Outcome Index (TOI)
percentage of evaluable participantsOlaparib 400 mg bdPlacebo bd
Improvement Rate for Trial Outcome Index (TOI)20.018.0
SecondaryImprovement Rate for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)

The percentage of patients with an improvement in total FACT-O. Improvement was defined as a change from baseline of greater than or equal to +9. \[Evaluable for FACT-O set\]

Time frame:
Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
Reported as:
Number · percentage of evaluable participants
Improvement Rate for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)
percentage of evaluable participantsOlaparib 400 mg bdPlacebo bd
Improvement Rate for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)21.118.9
SecondaryFACT-O Symptom Index (FOSI) Time to Worsening

The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for FOSI set\]

Time frame:
Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
Reported as:
Median · Months
FACT-O Symptom Index (FOSI) Time to Worsening
MonthsOlaparib 400 mg bdPlacebo bd
FACT-O Symptom Index (FOSI) Time to Worsening2.8 (1.8 to 3.7)3.7 (3.3 to 5.6)
Statistical analysis
  • Olaparib 400 mg bd vs Placebo bd · Regression, Cox · p = 0.22 · Hazard ratio (hr): 1.23 · 95% CI 0.88 to 1.71The model includes factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy.
SecondaryTrial Outcome Index(TOI)Time to Worsening

The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for TOI set\]

Time frame:
Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
Reported as:
Median · Months
Trial Outcome Index(TOI)Time to Worsening
MonthsOlaparib 400 mg bdPlacebo bd
Trial Outcome Index(TOI)Time to Worsening3.8 (2.8 to 7.4)4.6 (3.7 to 7.4)
Statistical analysis
  • Olaparib 400 mg bd vs Placebo bd · Regression, Cox · p = 0.67 · Hazard ratio (hr): 1.08 · 95% CI 0.75 to 1.56The model includes factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy.
SecondaryFunctional Analysis of Cancer Therapy - Ovarian (FACT-O) Time to Worsening

The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for FACT-O set\]

Time frame:
Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
Reported as:
Median · Months
Functional Analysis of Cancer Therapy - Ovarian (FACT-O) Time to Worsening
MonthsOlaparib 400 mg bdPlacebo bd
Functional Analysis of Cancer Therapy - Ovarian (FACT-O) Time to Worsening2.8 (1.9 to 4.7)4.6 (3.6 to 5.5)
Statistical analysis
  • Olaparib 400 mg bd vs Placebo bd · Regression, Cox · p = 0.38 · Hazard ratio (hr): 1.16 · 95% CI 0.83 to 1.64The model includes factors for treatment, ethnic descent, platinum sensitivity and response to final platinum therapy.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib 400 mg bd—31/136 (22.8%)129/136 (94.9%)
Placebo—11/128 (8.6%)111/128 (86.7%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventOlaparib 400 mg bdPlacebo
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders2/1363/128
ANAEMIABlood and lymphatic system disorders3/1360/128
GASTRITISGastrointestinal disorders0/1362/128
PANCYTOPENIABlood and lymphatic system disorders2/1360/128
CONSTIPATIONGastrointestinal disorders2/1360/128
FEMUR FRACTUREInjury, poisoning and procedural complications2/1360/128
DYSPNOEARespiratory, thoracic and mediastinal disorders2/1360/128
ABDOMINAL PAINGastrointestinal disorders0/1361/128
IMPAIRED GASTRIC EMPTYINGGastrointestinal disorders0/1361/128
INTESTINAL OBSTRUCTIONGastrointestinal disorders1/1361/128
Most frequent other events
Showing 10 of 44
Most frequent other events
EventOlaparib 400 mg bdPlacebo
NAUSEAGastrointestinal disorders96/13646/128
FATIGUEGeneral disorders73/13650/128
VOMITINGGastrointestinal disorders47/13618/128
ABDOMINAL PAINGastrointestinal disorders35/13634/128
DIARRHOEAGastrointestinal disorders36/13631/128
CONSTIPATIONGastrointestinal disorders30/13614/128
DECREASED APPETITEMetabolism and nutrition disorders29/13617/128
HEADACHENervous system disorders29/13617/128
DYSPEPSIAGastrointestinal disorders27/13611/128
ANAEMIABlood and lymphatic system disorders26/1367/128

Baseline characteristics

Age, Continuous
Age, Continuous(years)Olaparib 400 mg bdPlacebo bdTotal
Mean58.9 ± 10.9558.5 ± 9.8958.7 ± 10.43
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib 400 mg bdPlacebo bdTotal
Female136129265
Male000
Time to progression
Time to progression(participants)Olaparib 400 mg bdPlacebo bdTotal
>6 to 12 months5354107
>12 months8375158
Objective response
Objective response(Participants)Olaparib 400 mg bdPlacebo bdTotal
Complete response5763120
Partial response7966145
08

Study locations

107 sites
  • Research Site
    Berkeley, California 94704, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    West Hollywood, California 90048, United States
  • Research Site
    Sunrise, Florida 33027, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Providence, Rhode Island 02905, United States
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    East Bentleigh, 3165, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Nambour, 4560, Australia
  • Research Site
    Randwick, 2031, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Toorak Gardens, 5065, Australia
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Wein, 1130, Austria
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Quebec, G1R 2J6, Canada
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Praha 10, 100 34, Czechia
  • Research Site
    Tallinn, 11619, Estonia
  • Research Site
    Tartu, 51014, Estonia
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Caen Cedex, 14076, France
  • Research Site
    Lyon Cedex 08, 69373, France
  • Research Site
    Nantes, 44202, France
  • Research Site
    Paris, 75004, France
  • Research Site
    Paris, 75020, France
  • Research Site
    Reims Cedex, 51056, France
  • Research Site
    Bonn, 53105, Germany
  • Research Site
    Düsseldorf, 40217, Germany
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Freiburg, 79106, Germany
  • Research Site
    Göttingen, 37075, Germany
  • Research Site
    Hannover, 30177, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    Marburg, 35043, Germany
  • Research Site
    München, 81675, Germany
  • Research Site
    Rostock, 18059, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Wiesbaden, 65199, Germany
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Holon, 58100, Israel
  • Research Site
    Jerusalem, 91031, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Nahariya, 22100, Israel
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Tel-Aviv, 64239, Israel
  • Research Site
    Zerifin, 70300, Israel
  • Research Site
    Amsterdam, 1066 CX, Netherlands
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Białystok, 15-027, Poland
  • Research Site
    Grzepnica, 72-003, Poland
  • Research Site
    Lublin, 20 - 081, Poland
  • Research Site
    Poznan, 60-569, Poland
  • Research Site
    Poznan, 61-866, Poland
  • Research Site
    Poznań, Poland
  • Research Site
    Szczecin, 70-111, Poland
  • Research Site
    Warszawa, 02-781, Poland
  • Research Site
    Baia Mare, 430222, Romania
  • Research Site
    Cluj-Napoca, 400015, Romania
  • Research Site
    Iasi, 700106, Romania
  • Research Site
    Suceava, 720237, Romania
  • Research Site
    Barnaul, 656049, Russian Federation
  • Research Site
    Ekaterinburg, 620036, Russian Federation
  • Research Site
    Obninsk, 249036, Russian Federation
  • Research Site
    Orenburg, 460021, Russian Federation
  • Research Site
    Perm, 614066, Russian Federation
  • Research Site
    Pyatigorsk, 357502, Russian Federation
  • Research Site
    Saint-Petersburg, 197758, Russian Federation
  • Research Site
    St. Petersburg, 197002, Russian Federation
  • Research Site
    Voronezh, 394000, Russian Federation
  • Research Site
    Córdoba, 14004, Spain
  • Research Site
    Madrid, 08035, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Donetsk, 83092, Ukraine
  • Research Site
    Kharkiv Region, 61024, Ukraine
  • Research Site
    Kyiv, 03022, Ukraine
  • Research Site
    Kyiv, 03115, Ukraine
  • Research Site
    Lutsk, 43018, Ukraine
  • Research Site
    Odesa, 65009, Ukraine
  • Research Site
    Odesa, 65055, Ukraine
  • Research Site
    Ternopil, 46023, Ukraine
  • Research Site
    Uzhhorod, 88014, Ukraine
  • Research Site
    Dundee, DD1 9SY, United Kingdom
  • Research Site
    Edinburgh, EH4 2XR, United Kingdom

Showing the first 100 of 107 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PubMed 35170751 ↗
  • Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016 Nov 22;115(11):1313-1320. doi: 10.1038/bjc.2016.348. Epub 2016 Nov 8. PubMed 27824811 ↗
  • Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9. PubMed 27617661 ↗
  • Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016 Jun 15;122(12):1844-52. doi: 10.1002/cncr.29995. Epub 2016 Apr 8. PubMed 27062051 ↗
  • Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31. Erratum In: Lancet Oncol. 2015 Apr;16(4):e158. doi: 10.1016/S1470-2045(15)70153-1. PubMed 24882434 ↗
  • Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27. PubMed 22452356 ↗
  • Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583. PubMed 19238149 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2008 to primary completion in Jun 2010, 22 months.

Results were first posted in Mar 2013, 2 years 8 months after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 22 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2008
First posted
Sep 16, 2008
StartActual
Aug 28, 2008
Primary completionActual
Jun 30, 2010
CompletionActual
Oct 12, 2023
Results first posted
Mar 11, 2013
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00753545
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 16, 2008
Start date
Aug 28, 2008
Primary completion
Jun 30, 2010
Completion
Oct 12, 2023
Results posted
Mar 11, 2013
Last update
Feb 3, 2025

Study contacts

Mika Sovak, BSc, MBCHB, MD
study director · AstraZeneca
Prof Jonathan A Lederman
principal investigator · University College, London

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion